Clinical Trials Logo

Kidney Pancreas Transplant clinical trials

View clinical trials related to Kidney Pancreas Transplant.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04777617 Recruiting - Clinical trials for Kidney Pancreas Transplant

Allosure in Simultaneous Pancreas Kidney Transplant

Start date: February 26, 2021
Phase:
Study type: Observational

This study will observe donor derived cell free DNA percentages (via the Allosure test) in combined kidney-pancreas transplant recipients to establish both stable and dysfunctional Allosure assay levels

NCT ID: NCT01382355 Recruiting - Kidney Transplant Clinical Trials

Prospective Donor Specific Antibody (DSA) Monitoring Protocol

Start date: August 2011
Phase: N/A
Study type: Observational

Advances in transplant pharmacotherapy have led to improved one-year patient and graft survival in kidney transplant recipients, but have not translated to enhanced long-term survival. An explanation for the disparity in outcomes is the negative role of antibodies in transplant graft survival. There currently does not exist maintenance immunosuppression that targets antibodies and standard of practice aims at removing circulating donor specific antibodies upon detection of antibody mediated graft damage but not prior to the detection of rejection. There exists an insufficiency of data regarding patient and donor characteristics, changes in immunosuppression, the risk of viral donor and patient seropositivity and the risk of non-compliance on the development of antibodies. By measuring antibody levels in the blood at specific time periods after transplant, we may have a better understanding of what types of patients will develop antibodies, when these antibodies appear and how changes to transplant medications may affect antibodies. The proposed project will examine the multifactorial risks associated with the development and appearance of donor-specific antibodies in the first year post-kidney transplant. The data collected will provide a historical perspective and preliminary pilot data to support a proposal for prospective antibody monitoring and to justify pre-emptively treating the antibodies in the absence of clinical signs of rejection.